Abstracts tagged "interstitial lung disease"

Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
enrico De Lorenzis¹, Francesco Del Galdo², gerlando Natalello¹, Stefano Di Donato², lucrezia verardi¹, Vishal Kakkar², pier giacomo Cerasuolo¹, Francesco Varone³, Luca Richeldi³, Maria Antonietta D'Agostino¹ and Silvia Bosello¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…
Abstract Number: 1042 • ACR Convergence 2023
B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis
Shinji Watanabe¹, Keina Yomono², Shintaro Yamamoto¹, Mikito Suzuki³, Takahisa Gono⁴ and Masataka Kuwana⁴, ¹Nippon Medical School, Tokyo, Japan, ²Nippon Medical School University, Tokyo, Japan, ³Nippon Medical School Hospital, Tokyo, Japan, ⁴Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 0363 • ACR Convergence 2023
Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort
Michael Matt¹, Daniel Drozdov¹, Rolla Abu-Arja², Shanmuganathan Chandrakasan³, Kyla Driest², Elvira Cannizzaro Schneider⁴, Despina Moshous⁵, Benedicte Neven⁵, Karen Onel⁶, Sampath Prahalad⁷, Susan Prockop⁸, Pierre Quartier⁵, Johannes Roth⁹, Donna Wall¹⁰, Ulrike Zeilhofer¹¹, Scott Canna¹², Alexei Grom¹, Grant Schulert¹ and Rebecca Marsh¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Emory University School of Medicine, Atlanta, GA, ⁴Universitaetskinderspital Zurich, Zurich, Switzerland, ⁵Paris Cité Université and Necker Hospital, Paris, France, ⁶Hospital for Special Surgery, New York, NY, ⁷Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA, ⁸Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children's Hospital of Zurich, Zurich, Switzerland, ¹²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Refractory systemic juvenile idiopathic arthritis (sJIA) in children can be complicated by repeated episodes of macrophage activation syndrome (MAS) or sJIA-related lung disease (sJIA-LD).…
Abstract Number: 0662 • ACR Convergence 2023
Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giovanna Cuomo⁴, Lidia P Ananieva⁵, Eric Hachulla⁶, Vanessa Smith⁷, Ana Maria Gheorghiu⁸, Radim Becvar⁹, Nicolas Hunzelmann¹⁰, Daniel Furst¹¹, Vera Ortiz-Santamaria¹², Patricia Carreira¹³, Francesco Del Galdo¹⁴, marco Matucci Cerinic¹⁵ and Anna Maria Hoffmann-Vold¹⁶, ¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University of Lille, Lille, France, ⁷Ghent University Hospital, Gent, Belgium, ⁸Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ⁹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹⁰University of Kšln, Kšln, Germany, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Granollers, Granollers, Spain, ¹³Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: The treatment armamentarium with immunosuppressive treatments (ISTs) for interstitial lung disease (ILD) in systemic sclerosis (SSc) has greatly expanded. It is to date unclear…
Abstract Number: 1050 • ACR Convergence 2023
Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols
Fabian Carranza Enriquez¹, Carina Soto-Fajardo¹, Sinthia Solorzano Flores¹, Abish Angeles-Acuña¹, Mayra Mejia-Avila², Amyrari Vázquez-Ortega³, Paola Flores-Ordoñez², Karina Arias Callejas², Alejandra Enriquez-Luna⁴, Graciliano Ramon-Diaz⁴, Brenda Bravo-Zarate², Tatiana Sofía Rodríguez-Reyna³ and Carlos Pineda⁴, ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Rehabilitacion, Mexico City, Mexico
Background/Purpose: Lung ultrasound (LUS) has proven useful to detect interstitial lung disease (ILD) among patients with SSc when compared to high-resolution computerized tomography (HRCT) as…
Abstract Number: 1374 • ACR Convergence 2023
Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Marco Sprecher¹, Florine Weber², Kastriot Kastrati³, Helmut Prosch⁴, Natasha Moe⁵, Emily Langballe⁶, Cosimo Bruni⁷, Oyvind Molberg⁸, Phuong Phuong Diep⁹, Christian Clarenbach¹⁰, Paul Studenic¹¹, Helena Andersson⁸, Oyvind Midtvedt¹², Torhild Garen⁸, Karoline Lerang¹³, Thomas Frauenfelder¹⁴, Helga Radner¹⁵, Oliver Distler⁷ and Anna Maria Hoffmann-Vold¹⁶, ¹Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ⁴Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁵Dept of Radiology, University Hospital Oslo, Oslo, Norway, ⁶Universitetet i Oslo, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹¹Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁴Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…
Abstract Number: 1774 • ACR Convergence 2023
Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease
José Lisbona-Montañez¹, Patricia Ruiz-Limon², Arkaitz Mucientes³, Natalia Mena Vazquez⁴, Isabel Moreno-Indias³, SARA MANRIQUE⁵, Laura Cano-García⁶, Rocío Redondo-Rodríguez⁶, Francisco J tinahones³ and Antonio Fernandez-Nebro⁷, ¹Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, ²IBIMA Plataforma BIONAND, Cordoba, Spain, ³IBIMA Plataforma BIONAND, Málaga, Spain, ⁴IBIMA, Málaga, Spain, ⁵Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁷Hospital Regional Universitario de Málaga, Malaga, Spain
Background/Purpose: Gut microbiota has been related to rheumatoid arthritis (RA), inflammation, and it's severity. Interstitial lung disease (ILD) is the most frequent non-pleural pulmonary manifestation…
Abstract Number: 2188 • ACR Convergence 2023
Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Regis Sewa Marques, Maria Fernanda Zacarin, Pamela Bellini, Raissa Dudienas D Pereira, Aloma Guinami Scabora, Zoraida Sachetto, Manoel Bertolo and ALISSON PUGLIESI, Universidade Estadual de Campinas, Campinas, Brazil
Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…
Abstract Number: 0393 • ACR Convergence 2023
Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement
Florian Popp¹, Martin Hoffmann², Johannes von Kempis³, Martin Welcker¹, Werner von Wulffen² and Frank Reichenberger², ¹Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ²Augustinum Klinik München, Department of pneumology, Munich, Germany, ³Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland
Background/Purpose: Seropositive and ACPA positive Rheumatoid Arthritis (RA) is associated with significant cardiovascular and pulmonary comorbidity. However, screening for early detection of pulmonary involvement especially…
Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Kastriot Kastrati¹, Thomas S Nakuz², Oana C Kulterer², Stephan Blüml³, Michael Bonelli³, Irina Gessl⁴, Hans-Peter Kiener³, Werner Langsteger², Daniel Mrak³, Florian Prayer⁵, Helmut Prosch⁵, Elisabeth Simader³, Tatjana Traub-Weidinger², Daniel Aletaha⁶, Helga Radner⁷, Marcus Hacker² and Peter Mandl³, ¹Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
Abstract Number: 1137 • ACR Convergence 2023
Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease
Cristiana Sieiro Santos¹, Jose Luis Tandaipan², Diego Castillo², Laura Martínez Martínez², Helena Codes², Luis Sainz-Comas², Berta Paula Magallares-Lopez³, Patricia Moya², Anais Mariscal², Hye Sang Park², Ana Milena Millán Arciniegas², César Díaz-Torné², Ana Laíz Alonso², Sandra Ros², Susana Fernández², Hector Corominas⁴, Elvira Díez Álvarez⁵ and Iván Castellvi², ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ³Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ⁵CAULE, León, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
Abstract Number: 1377 • ACR Convergence 2023
Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study
Loïc Meudec¹, Cindy Marques², Pierre-Antoine Juge³, Robin Dhote⁴, Anne-Laure Fauchais⁵, Emanuelle Dernis⁶, Olivier Vittecoq⁷, Alain SARAUX⁸, Jacques-Eric Gottenberg⁹, Eric Hachulla¹⁰, Véronique Le Guern¹¹, Philippe Dieudé¹², Marie-Pierre Debray¹³, Antoine Beurnier¹⁴, Raphaele Seror¹⁵, Xavier Mariette¹⁶ and Gaetane Nocturne¹⁷, ¹CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, ²CHU Pitié Salpétrière, Internal Medicine 1, Paris, France, ³Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital, Boston, MA, ⁴Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, ⁵Dupuytren Hospital, Limoges, France, ⁶CH Le Mans, Le Mans, France, ⁷CHU Rouen, Rheumatology, Rouen, France, ⁸CHU Brest, Brest, France, ⁹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ¹¹APHP Hôpital Cochin, Paris, France, ¹²Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, ¹³CHU Bichat, Radiology, Paris, France, ¹⁴CHU Kremlin-Bicêtre, Functional Explorations, Le Kremlin-Bicêtre, France, ¹⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁶Université Paris-Saclay, Le Kremlin-Bicêtre, France, ¹⁷APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren disease (Sjo) is a systemic immune-related disease with pulmonary manifestations occurring in up to 16% of patients [1], including interstitial lung disease (SS-ILD)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].